<p>Transcode Therapeutics Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing lists Jack E. Stover as a Director of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-123775), on December 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

RNAZ

<p>Transcode Therapeutics Inc. has filed Form 3 with the SEC, listing Jack E. Stover as a Director. This filing is informational and not financial advice.</p>

Transcode Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Jack E. Stover